Navigation Links
Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
Date:2/18/2008

CAMBRIDGE, England, February 18 /PRNewswire/ -- Ranier Technology, a Cambridge UK based spinal implant development company, has secured an GBP8 million ($16 million) investment from new and existing investors to further develop and commercialise its motion preserving spinal implant products. The investment was made by Alliance Trust Equity Partners (ATEP) and First Ventures to fund the clinical testing and European launch of CAdisc L, the lumbar version of Ranier's compliant replacement spinal disc. In addition, the funding will enable the company to further develop and test CAdisc C - Ranier's total disc replacement for the cervical spine.

Commenting, Dr Geoffrey Andrews CEO and Founder of Ranier said, "We are delighted to have secured this funding from both new and existing high quality investors, and we warmly welcome ATEP as a new investor. This investment is strong validation of our CAdisc product technology and the exciting role our products will play in the burgeoning global spinal disc markets".

Ranier's CAdisc total disc replacement devices are designed to replace diseased spinal discs in both the lumbar (lower back) and cervical (neck) regions of the spine and to bring relief and a normal quality of life for younger patients (20 - 60 years old) who suffer debilitating pain from degenerative disc disease, and who do not wish to tolerate a major degradation to their life style.

The replacement spinal disc market is set to grow to over $2 billion per annum by 2015 and Ranier anticipates that its CAdisc products are well placed to take a significant proportion of that market. The CAdisc is a unique, entirely polymeric, shock absorbing design which allows the natural bio-mechanics of the spinal disc to be restored without the use of metal or sliding surfaces. CAdisc has been designed to be a highly durable, entirely MRI compatible implant, capable of protecting adjacent discs from accelerated degeneration observed with non-compliant spinal implants.

Richard Hope, Investor Director, ATEP commented, "We have been impressed by the company's focus in producing high quality spinal implant products and look forward to working with Ranier at this exciting time in its development".

Peter Wolfers of First Ventures commented, "We are pleased to continue our involvement with Ranier and to help the company take its family of total disc replacement products from the laboratory, through clinical study, and on into commercial markets. We look forward to seeing CAdisc's clinical benefits underpinning Ranier's commercial success."

In this investment round, Ranier were advised by specialist high technology fund raising and corporate finance advisors First Capital (London UK).

Notes to Editors

About Ranier Technology Limited

Ranier Technology, located in Cambridge, England, is a medical device developer utilising its proprietary Precision Polyurethane Manufacturing (PPM) technology to bring next generation, motion preservation spinal implants to clinical use.

http://www.ranier.co.uk

About Alliance Trust Equity Partners

ATEP is a wholly owned subsidiary of Alliance Trust PLC and is focussed on the provision of private equity finance. Alliance Trust PLC, a FTSE 100 company, is an international investment and financial services group, specialising in fund management, pensions and investment services. Alliance Trust PLC is currently the UK's largest generalist investment trust company investing on a global basis across all major markets and sectors.

Richard Hope led the transaction for ATEP and joined the board of Ranier on completion of the investment.

About First Ventures

FirstVentures advises FNI Venture Capital, the venture capital fund of the Nixdorf family, which invests in UK technology companies. FirstVentures has a particular specialisation and interest in companies which are exploiting opportunities based on advanced materials.

http://www.firstventures.co.uk

About First

FirstCapital is an investment bank specialising in fund raising and acquisitions advice for high growth technology companies. Established in 1999, it has offices in London and Cambridge. Clients include entrepreneurs, technology companies and investors in private companies. Services range from first round venture capital funding for technology companies to private equity exits for shareholders. Authorised and regulated by the Financial Services Authority, First Capital is a member of the British Venture Capital Association.
Capital http://www.firstcapital.co.uk

For further information please contact:

Dr Geoffrey Andrews

CEO Ranier Technology Limited

+44(0)1223-505045

geoffrey.andrews@ranier.co.uk


'/>"/>
SOURCE Ranier Technology Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Religion colors Americans views of nanotechnology
2. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
3. Technology Transforms Market Research in Pharmaceutical Industry
4. ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board
5. New Technology for Early Detection of Lung Cancer Selected for Clinical Study With Veterans
6. Fiber-based nanotechnology in clothing could harvest energy from physical movement
7. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
8. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
9. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
10. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
11. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
Breaking Biology Technology:
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):